Naltrexone controlled-release - Alkermes

Drug Profile

Naltrexone controlled-release - Alkermes

Alternative Names: Vivitrex; Vivitrol; XR-NTX

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alkermes
  • Developer Alkermes; Alkermes plc; Cephalon; Cilag GmbH International
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alcoholism; Opioid abuse
  • No development reported Drug abuse

Most Recent Events

  • 09 Jan 2017 Alkermes completes a phase III trial in Opioid abuse (Combination therapy) in USA (NCT02537574)
  • 01 Apr 2016 Alkermes initiates a phase III trial for Opioid abuse (Combination therapy) in USA (NCT02696434)
  • 31 Mar 2016 Efficacy and adverse events data from a phase II/III trial in Opioid abuse released by Alkermes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top